Novartis: encouraging data in MS
(CercleFinance.com) - On Thursday Novartis announced the publication in the New England Journal of Medicine (NEJM) of encouraging Phase III results for ofatumumab, its investigational treatment for relapsing-remitting multiple sclerosis.
According to the Swiss group, the cell therapy met its primary endpoints in two studies by achieving a "significant" reduction in the number of disease relapses on an annualised basis.
Both studies also demonstrated significant reductions in the severity of disability and the number of deep brain lesions, Novartis says.
The publication comes as the FDA and the European Medicines Agency (EMEA) are both reviewing this innovative treatment.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
According to the Swiss group, the cell therapy met its primary endpoints in two studies by achieving a "significant" reduction in the number of disease relapses on an annualised basis.
Both studies also demonstrated significant reductions in the severity of disability and the number of deep brain lesions, Novartis says.
The publication comes as the FDA and the European Medicines Agency (EMEA) are both reviewing this innovative treatment.
Copyright (c) 2020 CercleFinance.com. All rights reserved.